Plain-English translation of NCT06967740 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying the best ways to monitor and manage precancerous changes in the cervix, particularly in women who test positive for high-risk human papillomavirus (HPV). Researchers will track how these lesions naturally change over two years and test whether HPV vaccination status, viral load, and other markers can help predict which women need treatment and which can safely wait and watch.
Many women develop precancerous cervical changes that go away on their own, but doctors currently lack clear guidelines on which women can be safely monitored and which need immediate treatment. This study aims to create better guidelines that could spare some women from unnecessary procedures while keeping others safe.
You likely qualify if…
You likely don't qualify if…
You would join one of two groups: women who have never been vaccinated against HPV, or women who received HPV vaccination (Gardasil-9). Over two years, you would have regular follow-up visits with cervical exams, HPV testing, and possibly additional tests like viral load measurement and tissue analysis. The study aims to understand how your precancerous lesion changes naturally over time and whether certain HPV markers can predict whether treatment will be needed.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Czechia